Lindbrook Capital’s Faeth Therapeutics FTH Stock Holding History

Lindbrook Capital’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	2195
2021 Q3	$0	Buy	+1	New	+$182	﹤0.01%	1989

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Lindbrook Capital's FTH Position: Q4 2021 in Review

Lindbrook Capital sold out of Faeth Therapeutics (FTH) in Q4 2021, closing a stake of 1 share.

Lindbrook Capital first reported a position in FTH in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 37 funds tracked by Wall St. Rank hold FTH as of Q4 2021.

Lindbrook Capital reported no remaining Faeth Therapeutics position as of Q4 2021 after selling out during the quarter.
Lindbrook Capital sold 1 Faeth Therapeutics share in Q4 2021.
Lindbrook Capital first reported a position in Faeth Therapeutics in Q3 2021 and held it in 1 quarter.
Lindbrook Capital's Faeth Therapeutics position peaked at $0 in Q3 2021.
37 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.